1Dยท

$NVAX (-7.55%) | Novavax Q3 '24 Earnings Highlights:


๐Ÿ”น Revenue: $84.5M (Est. $61.3M) ๐ŸŸข

๐Ÿ”น Loss per Share: -$0.76 (Est. -$0.77) ๐ŸŸข

๐Ÿ”น R&D Expenses: $87.2M (Est. $104.1M) ๐ŸŸข

๐Ÿ”น Cash and Cash Equivalents: $573.6M (Est. $530.7M) ๐ŸŸข

๐Ÿ”น Product Sales: $38.2M (Est. $69.8M) ๐Ÿ”ด


FY24 Guidance:ย 

๐Ÿ”น Total Revenue: $650M - $700M (Prior: $700M - $800M) ๐Ÿ”ด

๐Ÿ”น Product Sales: $175M - $225M (Prior: $275M - $375M) ๐Ÿ”ด

๐Ÿ”น Licensing & Royalties: $475M (up from prior $425M) ๐ŸŸข


Key Highlights:ย 

๐Ÿ”ธ FDA lifted clinical hold on COVID-19-Influenza Combination vaccine, enabling Phase 3 trials.ย 

๐Ÿ”ธ Achieved authorization for updated 2024-2025 COVID-19 vaccine for ages 12+ in the U.S. and EU.ย 

๐Ÿ”ธ Partnership with Sanofi on track, with commercial responsibilities for Nuvaxovid to transfer in 2025.


Financial Overview:ย 

๐Ÿ”ธ Net Loss: $121M (DOWN from $131M YoY)

๐Ÿ”ธ Significant cost reductions in R&D and SG&A, down 26% YoY in Q3.


CEO Commentary:ย 

๐Ÿ”ธ "Focused on strategic growth beyond COVID-19, leveraging partnerships like Sanofi and expanding our proven technology platform."

4
2 Comments

profile image
โ€ขโ€ข
profile image
Sanofi buy it
โ€ขโ€ข
Join the conversation